WILLIAM B. SHUBB, District Judge.
Plaintiff Ixchel Pharma, LLC ("Ixchel") brought this action against defendant Biogen Inc. ("Biogen") asserting federal and state antitrust and state tort claims arising from an agreement that plaintiff entered into with non-party Forward Pharma FA ApS ("Forward") regarding the development of a pharmaceutical drug and a settlement agreement defendant entered into with Forward. Before the court is defendant's Motion to Dismiss the Second Amended Complaint pursuant to Federal Rule of Civil Procedure 12(b)(1) and 12(b)(6). (Docket No. 37.)
Plaintiff initiated this action alleging: (1) violation of the Sherman Act, 15 U.S.C. § 1; (2) tortious interference with contract; (3) intentional and negligent interference with prospective economic advantage; (4) violation of the California Cartwright Act, Cal. Bus. & Prof. Code § 16700,
On October 2, 2017, plaintiff filed a Second Amended Complaint ("SAC") asserting all of the same claims the court previously dismissed. (Docket No. 34.) In the Second Amended Complaint, plaintiff's Sherman and Cartwright Act claims remain unchanged from the First Amended Complaint. Plaintiff has amended its other claims and added (1) an allegation that defendant included an illegal "non-compete" provision in its agreement with Forward; (2) an allegation that Forward did not wait the necessary amount of time before it stopped working for plaintiff; and (3) additional facts related to speculative harms plaintiff allegedly suffered.
To bring a Sherman Act or Cartwright Act claim, a plaintiff must establish antitrust standing.
The court previously dismissed plaintiff's Sherman and Cartwright Act claims because it held that plaintiff had not alleged an antitrust injury. (Docket No. 25 at 7.) Plaintiff concedes its allegations as to these claims are identical to those in the First Amended Complaint. (Pl.'s Opp'n at 1 (Docket No. 40).) The court therefore dismisses them for the reasons discussed in the court's September 12 Order. (Docket No. 25 at 4-7.)
Although plaintiff's Second Amended Complaint pleads additional facts related to defendant's alleged tortious interference with contract, this claim continues to suffer from the same shortfalls this court identified in its September 12, 2017 Order granting defendant's Motion to dismiss the First Amended Complaint.
A claim for tortious interference with a contract requires the plaintiff allege: "(1) a valid contract between plaintiff and a third party; (2) defendant's knowledge of this contract; (3) defendant's intentional acts designed to induce a breach or disruption of the contractual relationship; (4) actual breach or disruption of the contractual relationship and (5) resulting damage."
In the Second Amended Complaint, plaintiff identifies two allegedly "wrongful means": (1) Forward's cessation of clinical trial work following termination of its agreement with plaintiff (SAC ¶ 64) and (2) Forward's failure to wait the required 60 days before ceasing its work with plaintiff after serving its notice of termination (SAC ¶ 62).
With regard to the first claim, plaintiff alleges that Forward breached an obligation to conduct clinical trials after its Collaboration Agreement with plaintiff had terminated. (FAC 34; SAC 64.) However, the court previously noted that such an obligation to continue with trials post-termination did not exist. (Docket No. 25 at 10.) Thus, defendant cannot be liable for inducing Forward to breach this nonexistent duty.
As to plaintiff's new claim that Forward failed to honor the full 60-day notice period, plaintiff does not allege that defendant instructed Forward not to wait the requisite time period. In fact, plaintiff merely indicates that defendant instructed Forward to terminate its existing contract with plaintiff, but has not alleged that defendant instructed Forward to in any way breach the existing contract or terminate it in such a way that would constitute a violation. To state a valid claim for tortious interference with a contract, plaintiff must allege that defendant's "intentional acts [were] designed to induce a breach or disruption of the contractual relationship" between Forward and plaintiff.
Additionally, plaintiff fails to allege any harm that resulted from this alleged early termination. Plaintiff does not, and seemingly cannot, allege that had Forward waited 60 days to cease its work on the clinical trials, plaintiff would have avoided the alleged speculative harms it asserts. Accordingly, even if plaintiff had satisfied the other requirements of a claim for tortious interference with a contract, plaintiff's failure to plead "resulting damage" means that its tortious interference claim based on this supposed breach would still warrant dismissal.
As with plaintiff's claim for intentional interference with a contract, plaintiff fails to allege independently wrongful conduct, a necessary requirement to sustain its claims for intentional and negligent interference with prospective economic advantage. (Docket No. 25 at 11.) Accordingly, the court must dismiss plaintiff's third and fourth causes of action.
California's Unfair Competition Law prohibits unfair competition, which is defined to include "any unlawful, unfair, or fraudulent business act or practice." Cal. Bus. & Prof. Code § 17200.
Because the court would dismiss all of plaintiff's other claims, as discussed above, the unlawful prong of the Unfair Competition Law is not met.
In an attempt to otherwise satisfy the unlawfulness requirement, plaintiff argues that defendant's inclusion of § 2.13 in the Forward-Biogen Agreement is an allegedly illegal "non-compete" provision that violates California Business & Professions Code § 16600 and New York common law. (SAC ¶¶ 56, 59, 113.) However, the court does not find that § 2.13 is in fact a non-compete agreement. The Forward-Biogen Agreement expressly preserves Forward's ability to compete against Biogen under the terms of a co-exclusive license. In fact, the Agreement explicitly permits Forward to "authoriz[e] contractors to perform services for [Forward], including services to manufacture or import products and to perform wholesale and distribution services for [Forward]." Forward-Biogen Agreement § 3.01. Therefore, § 2.13 clearly does not prevent Forward from developing and selling any pharmaceutical products containing DMF, as plaintiff asserts, and thus does not prevent Forward from competing with Biogen. Accordingly, this section cannot be classified as a "non-compete covenant," which Black's Law Dictionary defines as a commitment "not to engage in the same type of business." Black's Law Dictionary 420 (9th ed. 2009).
Rather than defining § 2.13 as some sort of illegal non-compete agreement, the court views it instead as an ancillary restraint, one that is subordinate to the larger, lawful agreement between Forward and defendant. Section 2.13 is merely a restriction that prevents Forward from competing with defendant in very limited and defined circumstances, and as such is not subject to the principles that govern non-competes as a matter of law.
The Supreme Court has explained that the Rule of Reason "has been regarded as a standard for testing the enforceability of covenants in restraint of trade which are ancillary to a legitimate transaction."
Although plaintiff argues that Section 16600, and not the Rule of Reason, should be applied in this case, California courts have concluded that Section 16600 does not apply outside of the employment context. The case law plaintiff relies on, notably
The Rule of Reason states that "the antitrust laws prohibit only those contracts which unreasonably restrain competition."
The court previously rejected plaintiff's First Amended Complaint, holding that the "allegations are limited to speculative harms to competition." (Docket No. 25 at 12.) The court finds that the Second Amended Complaint adds nothing new, and thus again must dismiss this cause of action for failure to plead harm to competition. Plaintiff re-invokes its allegation that, due to defendant's actions, it lost a $150,000 grant, (Pl.'s Opp'n at 49), but this allegation does not establish injury in fact as a lost grant does not constitute a harm to competition. Further, although plaintiff claims that the Second Amended Complaint added allegations that § 2.13 completely blocks Forward from competing with defendant, (
In the antitrust context, the unfairness prong of the Unfair Competition Law requires conduct "that threatens an incipient violation of an antitrust law, or violates the policy or spirit of one of those laws because its effects are comparable to or the same as a violation of the law, or otherwise significantly threatens or harms competition."
Here, plaintiff fails to identify and sufficiently allege conduct tethered to an actual or threatened impact on competition. As with the First Amended Complaint, plaintiff's allegations are limited to speculative harms to competition, as discussed above. (
IT IS THEREFORE ORDERED that defendant's Motion to Dismiss (Docket No. 37) be, and the same hereby is, GRANTED. The Second Amended Complaint is hereby DISMISSED. Plaintiff has already amended its complaint two times, and the court finds that further amendment as to plaintiff's first, second, third, and fourth claims would be futile. However, because plaintiff presented a new argument related to defendant's alleged violation of the California Unfair Competition Law, the court will grant plaintiff one more opportunity to amend its complaint with regard to this claim. Plaintiff has twenty days from the date this Order is signed to file a Third Amended Complaint, if it can do so consistent with this order.